Search research articles
Contact Us
Filters
Showing results (111-120 of 154) with videos related to
Page
of 16
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
Jürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
The New England Journal of Medicine
|
March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Judith Aberg, Gilles Pialoux, et al.
Antiviral Therapy
|
February 27, 2013
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C
Jacob Lalezari, Terry Box, William O'Riordan, et al.
HIV Clinical Trials
|
August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
Edwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV
|
February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Alan Winston, Frank A Post, Edwin DeJesus, et al.
BMC Infectious Diseases
|
June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
Edward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
The Journal of Antimicrobial Chemotherapy
|
August 13, 2013
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
George L Melikian, Soo-Yon Rhee, Vici Varghese, et al.
The Lancet. HIV
|
February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Joseph J Eron, Susan J Little, Gordon Crofoot, et al.
Antimicrobial Agents and Chemotherapy
|
May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 154) with videos related to
Sort By:
Page
of 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
Jürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
The New England Journal of Medicine
|
March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Judith Aberg, Gilles Pialoux, et al.
Antiviral Therapy
|
February 27, 2013
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C
Jacob Lalezari, Terry Box, William O'Riordan, et al.
HIV Clinical Trials
|
August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK
Edwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV
|
February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Alan Winston, Frank A Post, Edwin DeJesus, et al.
BMC Infectious Diseases
|
June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
Edward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
The Journal of Antimicrobial Chemotherapy
|
August 13, 2013
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
George L Melikian, Soo-Yon Rhee, Vici Varghese, et al.
The Lancet. HIV
|
February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Joseph J Eron, Susan J Little, Gordon Crofoot, et al.
Antimicrobial Agents and Chemotherapy
|
May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Page
of 16